ArticleBMC cancer2026
Use of cell-free DNA in early detection of lung cancer: a proof-of concept study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-dose computed tomography (LDCT) remains the only validated modality for lung cancer screening, yet participation is suboptimal. Blood-based assays could eventually complement LDCT, but their performance for detecting early-stage disease in screening populations is uncertain. This study evaluated how well a cell-free DNA blood-based screening test can detect early-stage lung cancer in patients with LDCT screen-detected or incidental lung nodules.
methodsWe recruited patients via email with upcoming LDCT appointments whose results were classified under the Lung-RADS categories of 1–4. Guardant Health LUNAR® test collection kits were mailed to the participant. Participants provided a blood sample on the day of their LDCT visit, or within 30 days of the scan. Sensitivity and specificity were computed using the tumor registry as the gold standard and compared to assay results from the blood draw date closest to the date of diagnosis of cancer, but prior to receipt of any treatment.
resultsOf the 765 participants, 18 lung cancers were diagnosed. Most of the study population had a previous lung cancer screen. Eleven cases were diagnosed with stage 1 disease (68.8%). The sensitivity was 43.8% (95% CI:19.4–68.1%) and the specificity was 84.1% (95% CI: 81.5–86.7%), which resulted in a false positive rate of 15.9%. The negative predictive value was 98.6% and the positive predictive value was 5.6%. Exploratory stage-adjusted sensitivity was 75.4% (95% CI:63.6–87.2%).
conclusionsThe cfDNA assay demonstrated moderate specificity but limited sensitivity. Given the false positive rate of 15.9%, our results suggest that cfDNA-based assays for lung cancer may play a role as tools in combination with existing screening strategies pending continued validation. This proof-of-concept study is an important step in determining the feasibility of blood-based testing for early lung cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.